Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy

2022 ◽  
Author(s):  
Emi Hibino ◽  
Hidekazu Hiroaki
Keyword(s):  
Cancer Therapy ◽  
Tumor Suppressor ◽  
Tumor Suppressor P53

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

2014 ◽  
Vol 15 (1) ◽  
pp. 80-89 ◽  
Author(s):  
Bo Hong ◽  
A. Heuvel ◽  
Varun Prabhu ◽  
Shengliang Zhang ◽  
Wafik El-Deiry
Keyword(s):  
Cancer Therapy ◽  
Tumor Suppressor ◽  
Tumor Suppressor P53 ◽  
Challenges And Opportunities ◽  
Therapy Strategies

Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils

2018 ◽  
Author(s):  
Mohammad S. Safari ◽  
Zhiqing Wang ◽  
Kunaal Tailor ◽  
Anatoly B. Kolomeisky ◽  
Jacinta C. Conrad ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Tumor Suppressor P53 ◽  
Dense Liquid

Expanding the Biotherapeutics Realm via miR-34a: “Potent Clever Little” Agent in Breast Cancer Therapy

2019 ◽  
Vol 20 (8) ◽  
pp. 665-673 ◽  
Author(s):  
Mohsen Mohammady ◽  
Seyed I. Ghetmiri ◽  
Mahtab Baharizade ◽  
Mohammad H. Morowvat ◽  
Susan Torabi
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Tumor Suppressor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Signal Pathways ◽  
Breast Cancer Therapy ◽  
Female Population ◽  
Therapeutic Goals ◽  
Normal Tissues

Background:One of the most prevalent cancers befell to women is considered to be breast cancer (BC). It is also the deadliest among the female population after lung cancer. Additionally, several studies have demonstrated that there is an association between microRNA34-a and breast cancer.Method:We searched PubMed, Web of Science, and Google Scholar up to December 2018. Those studies which have been studied miR-34a and its tumor-suppressing capabilities were considered as the most important topics. Moreover, we extracted articles which were solely focused on microRNA-34a in breast cancer therapy. Finally, 80 articles were included.Results:In comparison with the normal tissues, down-regulation of miR-34a expression is shown considerably in tumor cells. Overexpression of miR-34a acts as a tumor suppressor by transcriptional regulating one of the signaling pathways (TP53), NOTCH, and transforming growth factor beta (TGF-β), Bcl- 2 and SIRT1genes, HDAC1 and HDAC7, Fra-1, TPD52, TLR Via CXCL10. Moreover, drug resistance declines which lead to the apoptosis, cell cycle arrest and senescence. As a result, the proliferation, invasion and metastasis of the tumor are suppressed. The Mrx34 drug contains miR-34a mimic and a lipid vector. MiR-34a as the active ingredient portrays the role of a tumor suppressor. This drug has recently entered the clinical trials studies.Conclusion:These findings suggest a robust cause for developing miR-34a as a therapeutic agent to target BC. In that scenario, miR-34a is strongly useful to introduce new therapeutic goals for BC. Moreover, this review aims to confirm the signal pathways, therapeutic and diagnostic values of miR- 34a in BC and beyond.

The Sumoylation Modulated Tumor Suppressor p53 Regulates Cell Cycle Checking Genes to Mediate Lens Differentiation

2019 ◽  
Vol 18 (8) ◽  
pp. 556-565 ◽  
Author(s):  
Xiangcheng Tang ◽  
Zhigang Chen ◽  
Mi Deng ◽  
Ling Wang ◽  
Qian Nie ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Tumor Suppressor ◽  
Tumor Suppressor P53
Sign in / Sign up

Export Citation Format

Share Document